World Heart Federation Roadmap on Atrial Fibrillation – A 2020 Update
By: Ben Freedman, Gerhard Hindricks, Amitava Banerjee, Adrian Baranchuk, Chi Keong Ching, Xin Du, Donna Fitzsimons, Jeff S. Healey, Takanori Ikeda, Trudie C. A. Lobban, Amam Mbakwem, Calambur Narasimhan, Lis Neubeck, Peter Noseworthy, Daniel M. Philbin, Fausto J. Pinto, Joselyn Rwebembera, Renate B. Schnabel, Jesper Hastrup Svendsen, Luis Aguinaga, Elena Arbelo, Michael Böhm, Hasan Ali Farhan, F. D. Richard Hobbs, Antoni Martínez-Rubio, Claudio Militello, Nitish Naik, Jean Jacques Noubiap, Pablo Perel, Daniel José Piñero, Antonio Luiz Ribeiro and Janina Stepinska
References
- Murphy A, Banerjee A, Breithardt G, Camm AJ, Commerford P, Freedman B, et al. The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. Glob Heart. 2017; 12(4): 273–84. DOI: 10.1016/j.gheart.2017.01.015
- Zaidel EJ, Leng X, Adeoye AM, Hakim F, Karmacharya B, Katbeh A, et al. Inclusion in the World Health Organization Model List of Essential Medicines of Non-Vitamin K Anticoagulants for Treatment of Non-Valvular Atrial Fibrillation: A Step Towards Reducing the Burden of Cardiovascular Morbidity and Mortality. Glob Heart. 2020; 15(1): 52. DOI: 10.5334/gh.608
- Chugh SS, Roth GA, Gillum RF, Mensah GA. Global Burden of Atrial Fibrillation in Developed and Developing Nations. Glob Heart. 2014; 9(1): 113–9. DOI: 10.1016/j.gheart.2014.01.004
- Wann LS, Alpert LS, Calkins H, Cigarroa JE, Cleveland JC,
Jr. , et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014; 64(21): e1–e76. - Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016; 37(38): 2893–962. DOI: 10.1093/eurheartj/ehw210
- Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide Epidemiology of Atrial Fibrillation. Circulation. 2014; 129(8): 837–47. DOI: 10.1161/CIRCULATIONAHA.113.005119
- Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective National Study of the Prevalence, Incidence, Management and Outcome of a Large Contemporary Cohort of Patients With Incident Non-Valvular Atrial Fibrillation. J Am Heart Assoc. 2015; 4(1):
e001486 . DOI: 10.1161/JAHA.114.001486 - Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited. Stroke. 2013; 44(11): 3103–8. DOI: 10.1161/STROKEAHA.113.002329
- Heeringa J, van der Kuip DAM, Hofman A, Kors JA, van Herpen G, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J. 2006; 27(8): 949–53. DOI: 10.1093/eurheartj/ehi825
- Nielsen JC, Lin YJ, de Oliveira Figueiredo MJ, Sepehri Shamloo A, Alfie A, Boveda S, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: Use the right tool for the right outcome, in the right population. Europace. 2020; 22(8): 1147–8. DOI: 10.1093/europace/euaa065
- Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime Risk for Development of Atrial Fibrillation. Circulation. 2004; 110(9): 1042–6. DOI: 10.1161/01.CIR.0000140263.20897.42
- Mou L, Norby FL, Chen LY, O’Neal WT, Lewis TT, Loehr LR, et al. Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol. 2018; 11(7):
e006350 . DOI: 10.1161/CIRCEP.118.006350 - Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25): 2982–3021. DOI: 10.1016/j.jacc.2020.11.010
- Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014; 6: 213–20. DOI: 10.2147/CLEP.S47385
- Krijthe BP, Kunst A, Benjamin EJ, Lip GYH, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013; 34(35): 2746–51. DOI: 10.1093/eurheartj/eht280
- Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population. American Journal of Cardiology. 2013; 112(8): 1142–7. DOI: 10.1016/j.amjcard.2013.05.063
- Naser N, Dilic M, Durak A, Kulic M, Pepic E, Smajic E, et al. The Impact of Risk Factors and Comorbidities on The Incidence of Atrial Fibrillation. Mater Sociomed. 2017; 29(4): 231–6. DOI: 10.5455/msm.2017.29.231-236
- Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost. 2013; 110(2): 213–22. DOI: 10.1160/TH13-02-0165
- Lowres N, Olivier J, Chao TF, Chen SA, Chen Y, Diederichsen A, et al. Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: A multicountry patient-level meta-analysis of 141,220 screened individuals. PLoS Med. 2019; 16(9):
e1002903 . DOI: 10.1371/journal.pmed.1002903 - Marcus GM, Alonso A, Peralta CA, Lettre G, Vittinghoff E, Lubitz SA, et al. European Ancestry as a Risk Factor for Atrial Fibrillation in African Americans. Circulation. 2010; 122(20): 2009–15. DOI: 10.1161/CIRCULATIONAHA.110.958306
- Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, et al. Incidence of atrial fibrillation in whites and African-Americans: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009; 158(1): 111–7. DOI: 10.1016/j.ahj.2009.05.010
- Jensen PN, Thacker EL, Dublin S, Psaty BM, Heckbert SR. Racial Differences in the Incidence of and Risk Factors for Atrial Fibrillation in Older Adults: The Cardiovascular Health Study. J Am Geriatr Soc. 2013; 61(2): 276–80. DOI: 10.1111/jgs.12085
- Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident Atrial Fibrillation Among Asians, Hispanics, Blacks, and Whites. Circulation. 2013; 128(23): 2470–7. DOI: 10.1161/CIRCULATIONAHA.113.002449
- Soni A, Earon A, Handorf A, Fahey N, Talati K, Bostrom J, et al. High Burden of Unrecognized Atrial Fibrillation in Rural India: An Innovative Community-Based Cross-Sectional Screening Program. JMIR public health and surveillance. 2016; 2(2):
e159 . DOI: 10.2196/publichealth.6517 - Soni A, Karna S, Fahey N, Sanghai S, Patel H, Raithatha S, et al. Age-and-sex stratified prevalence of atrial fibrillation in rural Western India: Results of SMART-India, a population-based screening study. Int J Cardiol. 2019; 280: 84–8. DOI: 10.1016/j.ijcard.2018.12.016
- Hingorani P, Natekar M, Deshmukh S, Karnad DR, Kothari S, Narula D, et al. Morphological abnormalities in baseline ECGs in healthy normal volunteers participating in phase I studies. Indian J Med Res. 2012; 135(3): 322–30.
- Saggu DK, Sundar G, Nair SG, Bhargava VC, Lalukota K, Chennapragada S, et al. Prevalence of atrial fibrillation in an urban population in India: The Nagpur pilot study. Heart Asia. 2016; 8(1): 56–9.
- Chan N-y, Choy C-c. Screening for atrial fibrillation in 13,122 Hong Kong citizens with smartphone electrocardiogram. Heart. 2017; 103(1): 24–31. DOI: 10.1136/heartjnl-2016-309993
- Noubiap JJ, Nyaga UF. A review of the epidemiology of atrial fibrillation in sub-Saharan Africa. J Cardiovasc Electrophysiol. 2019; 30(12): 3006–16. DOI: 10.1111/jce.14222
- Mandi DG, Bamouni J, Naïbé DT, Yaméogo RA, Kaboré E, Kambiré Y, et al. Epidemiology and long-term prognosis of atrial fibrillation in rural African patients. The Egyptian Heart Journal. 2019; 71(1): 6. DOI: 10.1186/s43044-019-0005-3
- Gouda HN, Charlson F, Sorsdahl K, Ahmadzada S, Ferrari AJ, Erskine H, et al. Burden of non-communicable diseases in sub-Saharan Africa, 1990–2013; 2017: Results from the Global Burden of Disease Study 2017. The Lancet Global Health. 2019; 7(10): e1375–e87. DOI: 10.1016/S2214-109X(19)30374-2
- Lau C-P, Gbadebo TD, Connolly SJ, Van Gelder IC, Capucci A, Gold MR, et al. Ethnic Differences in Atrial Fibrillation Identified Using Implanted Cardiac Devices. J Cardiovasc Electrophysiol. 2013; 24(4): 381–7. DOI: 10.1111/jce.12066
- Muthalaly RG, Koplan BA, Albano A, North C, Campbell JI, Kakuhikire B, et al. Low population prevalence of atrial fibrillation in rural Uganda: A community-based cross-sectional study. Int J Cardiol. 2018; 271: 87–91. DOI: 10.1016/j.ijcard.2018.05.074
- Paixão GMM, Silva LGS, Gomes PR, Lima EM, Ferreira MPF, Oliveira DM, et al. Evaluation of Mortality in Atrial Fibrillation: Clinical Outcomes in Digital Electrocardiography (CODE) Study. Glob Heart. 2020; 15(1): 48. DOI: 10.5334/gh.772
- Marcolino MS, Palhares DM, Benjamin EJ, Ribeiro AL. Atrial fibrillation: prevalence in a large database of primary care patients in Brazil. Europace. 2015; 17(12): 1787–90. DOI: 10.1093/europace/euv185
- Mora-Llabata DD-MV, Roldán-Torres I, Mateu-Navarro C, Sanz-García JJ, Moreno-Ballester V, Mira-Gimeno S, Albiñana-Fernández F. Prevalencia de fibrilación auricular y características de la fibrilación auricular no valvular en la población general. Revista Colombiana de Cardiología. 2017; 24(1): 26–33. DOI: 10.1016/j.rccar.2016.03.021
- Cubillos L, Haddad A, Kuznik A, Mould-Quevedo J. Burden of disease from atrial fibrillation in adults from seven countries in Latin America. Int J Gen Med. 2014; 7: 441–8. DOI: 10.2147/IJGM.S62819
- Joseph PG, Healey JS, Raina P, Connolly SJ, Ibrahim Q, Gupta R, et al. Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153,152 middle-aged individuals. Cardiovasc Res; 2020. DOI: 10.1093/cvr/cvaa241
- Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: Perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013; 8(5):
e63479 . DOI: 10.1371/journal.pone.0063479 - Goto S, Oh S, Cools F, Koretsune Y, Angchaisuksiri P, Rushton-Smith S, et al. Regional differences in use of antithrombotic therapy for stroke prevention in atrial fibrillation and associated outcomes: European and Asian insights. Eur Heart J. 2013; 34: P4277. DOI: 10.1093/eurheartj/eht309.P4277
- Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol. 2013; 167(6): 2412–20. DOI: 10.1016/j.ijcard.2013.01.184
- Narasimhan C, Verma JS, Ravi Kishore AG, Singh B, Dani S, Chawala K, et al. Cardiovascular risk profile and management of atrial fibrillation in India: Real world data from RealiseAF survey. Indian Heart J. 2016; 68(5): 663–70. DOI: 10.1016/j.ihj.2015.12.011
- Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: The RE-LY Atrial Fibrillation Registry. Circulation. 2014; 129(15): 1568–76. DOI: 10.1161/CIRCULATIONAHA.113.005451
- Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of Atrial Fibrillation on the Risk of Death. Circulation. 1998; 98(10): 946–52. DOI: 10.1161/01.CIR.98.10.946
- Stewart S, Hart CL, Hole DJ, McMurray JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002; 113(5): 359–64. DOI: 10.1016/S0002-9343(02)01236-6
- Andersson T, Magnuson A, Bryngelsson I-L, Frøbert O, Henriksson KM, Edvardsson N, et al. All-cause mortality in 272 186 patients hospitalized with incident atrial fibrillation 1995–2008: A Swedish nationwide long-term case-control study. Eur Heart J. 2013; 34(14): 1061–7. DOI: 10.1093/eurheartj/ehs469
- Sepehri Shamloo A, Dagres N, Müssigbrodt A, Stauber A, Kircher S, Richter S, et al. Atrial Fibrillation and Cognitive Impairment: New Insights and Future Directions. Heart Lung Circ. 2020; 29(1): 69–85. DOI: 10.1016/j.hlc.2019.05.185
- Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart Disease and Stroke Statistics 2014; 2018 Update: A Report From the American Heart Association. Circulation. 2018; 137(12): e67–e492. DOI: 10.1161/CIR.0000000000000573
- PricewaterhouseCoopers. Commissioned by the National Stroke Foundation. The Economic Costs of Atrial Fibrillation in Australia. 2010.25/6/2020. Available from:
http://www.hps.com.au/wp-content/uploads/2016/10/Economic-costs-of-atrial-fibrillation-in-Australia.pdf . - Freedman B, Camm J, Calkins H, Healey JS, Rosenqvist M, Wang J, et al. Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. Circulation. 2017; 135(19): 1851–67. DOI: 10.1161/CIRCULATIONAHA.116.026693
- Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50-year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. The Lancet. 2015; 386(9989): 154–62. DOI: 10.1016/S0140-6736(14)61774-8
- Menezes AR, Lavie CJ, De Schutter A, Milani RV, O’Keefe J, DiNicolantonio JJ, et al. Lifestyle modification in the prevention and treatment of atrial fibrillation. J Progress in cardiovascular diseases. 2015; 58(2): 117–25. DOI: 10.1016/j.pcad.2015.07.001
- Du X, Dong J, Ma C. Is atrial fibrillation a preventable disease? J Am Coll Cardiol. 2017; 69(15): 1968–82. DOI: 10.1016/j.jacc.2017.02.020
- Ahmadi SS, Svensson A-M, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: A Swedish cohort study. J Cardiovascular diabetology. 2020; 19(1): 1–12. DOI: 10.1186/s12933-019-0983-1
- Murphy NF, Simpson CR, Jhund PS, Stewart S, Kirkpatrick M, Chalmers J, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. J Heart. 2007; 93(5): 606–12. DOI: 10.1136/hrt.2006.107573
- Misialek JR, Rose KM, Everson-Rose SA, Soliman EZ, Clark CJ, Lopez FL, et al. Socioeconomic status and the incidence of atrial fibrillation in whites and blacks: The Atherosclerosis Risk in Communities (ARIC) study. J Am Heart Assoc. 2014; 3(4):
e001159 . DOI: 10.1161/JAHA.114.001159 - Wändell P, Carlsson AC, Gasevic D, Holzmann MJ, Ärnlöv J, Sundquist J, et al. Socioeconomic factors and mortality in patients with atrial fibrillation—a cohort study in Swedish primary care. European J of public health. 2018; 28(6): 1103–9. DOI: 10.1093/eurpub/cky075
- Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: The ARREST-AF cohort study. J Am Coll Cardiol. 2014; 64(21): 2222–31. DOI: 10.1016/j.jacc.2014.09.028
- Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: A randomized clinical trial. JAMA. 2013; 310(19): 2050–60. DOI: 10.1001/jama.2013.280521
- Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, et al. Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol. 2015; 65(20): 2159–69. DOI: 10.1016/j.jacc.2015.03.002
- Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ. 1998; 316(7147): 1784–5. DOI: 10.1136/bmj.316.7147.1784
- Baldesberger S, Bauersfeld U, Candinas R, Seifert B, Zuber M, Ritter M, et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur Heart J. 2008; 29(1): 71–8. DOI: 10.1093/eurheartj/ehm555
- Molina L, Mont L, Marrugat J, Berruezo A, Brugada J, Bruguera J, et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace. 2008; 10(5): 618–23. DOI: 10.1093/europace/eun071
- Nielsen JR, Wachtell K, Abdulla J. The Relationship Between Physical Activity and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis. J Atr Fibrillation. 2013; 5(5): 789.
- Epstein LJ, Kristo D, Strollo PJ,
Jr. , Friedman N, Malhotra A, Patil SP, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009; 5(3): 263–76. DOI: 10.5664/jcsm.27497 - Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Levy P, et al. Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment: A Review. JAMA Cardiol. 2018; 3(6): 532–40. DOI: 10.1001/jamacardio.2018.0095
- Kotseva K, De Backer G, De Bacquer D, Rydén L, Hoes A, Grobbee D, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019; 26(8): 824–35. DOI: 10.1177/2047487318825350
- Proia KK, Thota AB, Njie GJ, Finnie RK, Hopkins DP, Mukhtar Q, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014; 47(1): 86–99. DOI: 10.1016/j.amepre.2014.03.004
- Buhse S, Mühlhauser I, Heller T, Kuniss N, Müller UA, Kasper J, et al. Informed shared decision-making programme on the prevention of myocardial infarction in type 2 diabetes: a randomised controlled trial. BMJ open. 2015; 5(11):
e009116 . DOI: 10.1136/bmjopen-2015-009116 - Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 74(10): e177–e232.
- Johansson C, Dahlqvist E, Andersson J, Jansson JH, Johansson L. Incidence, type of atrial fibrillation and risk factors for stroke: A population-based cohort study. Clin Epidemiol. 2017; 9: 53–62. DOI: 10.2147/CLEP.S122916
- Healey JS, Alings M, Ha A, Leong-Sit P, Birnie DH, de Graaf JJ, et al. Subclinical Atrial Fibrillation in Older Patients. Circulation. 2017; 136(14): 1276–83. DOI: 10.1161/CIRCULATIONAHA.117.028845
- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J; 2020.
- Ganesan AN, Chew DP, Hartshorne T, Selvanayagam JB, Aylward PE, Sanders P, et al. The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: A systematic review and meta-analysis. Eur Heart J. 2016; 37(20): 1591–602. DOI: 10.1093/eurheartj/ehw007
- Israel CW, Grönefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: Implications for optimal patient care. J Am Coll Cardiol. 2004; 43(1): 47–52. DOI: 10.1016/j.jacc.2003.08.027
- Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, et al. Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149(4): 657–63. DOI: 10.1016/j.ahj.2004.06.032
- Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. Am J Med. 2015; 128(5): 509–18.e2. DOI: 10.1016/j.amjmed.2014.11.026
- Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, et al. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. Int J Cardiol. 2013; 167(6): 2682–7. DOI: 10.1016/j.ijcard.2012.06.118
- Jabaudon D, Sztajzel J, Sievert K, Landis T, Sztajzel R. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke. 2004; 35(7): 1647–51. DOI: 10.1161/01.STR.0000131269.69502.d9
- Edwards SJ, Wakefield V, Jhita T, Kew K, Cain P, Marceniuk G. Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke: a systematic review and economic evaluation. Health Technol Assess. 2020; 24(5): 1–184. DOI: 10.3310/hta24050
- Schnabel RB, Haeusler KG, Healey JS, Freedman B, Boriani G, Brachmann J, et al. Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. Circulation. 2019; 140(22): 1834–50. DOI: 10.1161/CIRCULATIONAHA.119.040267
- Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019; 381(20): 1909–17. DOI: 10.1056/NEJMoa1901183
- Brasier N, Raichle CJ, Dörr M, Becke A, Nohturfft V, Weber S, et al. Detection of atrial fibrillation with a smartphone camera: first prospective, international, two-centre, clinical validation study (DETECT AF PRO). Europace. 2019; 21(1): 41–7. DOI: 10.1093/europace/euy176
- Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, et al. Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. J Am Coll Cardiol. 2019; 74(19): 2365–75. DOI: 10.1016/j.jacc.2019.08.019
- Castaneda D, Esparza A, Ghamari M, Soltanpur C, Nazeran H. A review on wearable photoplethysmography sensors and their potential future applications in health care. Int J Biosens Bioelectron. 2018; 4(4): 195–202. DOI: 10.15406/ijbsbe.2018.04.00125
- Dörr M, Nohturfft V, Brasier N, Bosshard E, Djurdjevic A, Gross S, et al. The WATCH AF Trial: SmartWATCHes for Detection of Atrial Fibrillation. JACC Clin Electrophysiol. 2019; 5(2): 199–208. DOI: 10.1016/j.jacep.2018.10.006
- Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. N Engl J Med. 2019; 381(20): 1909–17. DOI: 10.1056/NEJMoa1901183
- Cheung CC, Gin KG, Andrade JG. Watch Out: The Many Limitations in Smartwatch-Driven AF Detection. JACC Clin Electrophysiol. 2019; 5(4): 525–6. DOI: 10.1016/j.jacep.2019.02.008
- Statista. Wearable user penetration rate in the United States, in 2017, by age; 2020.
- National Institute for Health and Care Excellence (NICE). WatchBP Home A for opportunistically detecting atrial fibrillation during diagnosis and monitoring of hypertension; 2013:
https://www.nice.org.uk/guidance/mtg13 . - Yan BP, Lai WHS, Chan CKY, Au ACK, Freedman B, Poh YC, et al. High-Throughput, Contact-Free Detection of Atrial Fibrillation From Video With Deep Learning. JAMA Cardiol. 2020; 5(1): 105–7. DOI: 10.1001/jamacardio.2019.4004
- Nijasri C, Suwanwela AC, Autjimanon H, Ounahachok T, Decha-umphai C, Chockchai S, et al. Atrial fibrillation prevalence and risk profile from novel community-based screening in Thailand: A prospective multi-centre study. IJC Heart & Vasculature. 2021; 32. DOI: 10.1016/j.ijcha.2020.100709
- Behzadi A, Sepehri Shamloo A, Mouratis K, Hindricks G, Arya A, Bollmann A. Feasibility and Reliability of SmartWatch to Obtain 3-Lead Electrocardiogram Recordings. Sensors (Basel). 2020; 20(18). DOI: 10.3390/s20185074
- Bumgarner JM, Lambert CT, Hussein AA, Cantillon DJ, Baranowski B, Wolski K, et al. Smartwatch Algorithm for Automated Detection of Atrial Fibrillation. J Am Coll Cardiol. 2018; 71(21): 2381–8. DOI: 10.1016/j.jacc.2018.03.003
- Gwynn J, Gwynne K, Rodrigues R, Thompson S, Bolton G, Dimitropoulos Y, et al. Atrial Fibrillation in Indigenous Australians: A Multisite Screening Study Using a Single-Lead ECG Device in Aboriginal Primary Health Settings. Heart Lung Circ; 2020. DOI: 10.1016/j.hlc.2020.06.009
- Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening for Untreated Atrial Fibrillation: The Strokestop Study. Circulation. 2015; 131(25): 2176–84. DOI: 10.1161/CIRCULATIONAHA.114.014343
- Diamantino AC, Nascimento BR, Beaton AZ, Nunes MCP, Oliveira KKB, Rabelo LC, et al. Atrial fibrillation detection with a portable device during cardiovascular screening in primary care. Heart. 2020; 106(16): 1261–6. DOI: 10.1136/heartjnl-2019-316277
- Silver LSA, Johnson C, Taylor K, Jiang J, Anderson M, Rainie L. Mobile Connectivity in Emerging Economies Pew Research Center; 2019.
- Communications TGSfM. The Mobile Economy 2020; 2020.
- Boriani G, Schnabel RB, Healey JS, Lopes RD, Verbiest-van Gurp N, Lobban T, et al. Consumer-led screening for atrial fibrillation using consumer-facing wearables, devices, and apps: A survey of health care professionals by AF-SCREEN international collaboration. Eur J Intern Med; 2020. DOI: 10.1016/j.ejim.2020.09.005
- Lopez-Jimenez F, Attia Z, Arruda-Olson AM, Carter R, Chareonthaitawee P, Jouni H, et al. Artificial Intelligence in Cardiology: Present and Future. Mayo Clin Proc. 2020; 95(5): 1015–39. DOI: 10.1016/j.mayocp.2020.01.038
- Attia ZI, Noseworthy PA, Lopez-Jimenez F, Asirvatham SJ, Deshmukh AJ, Gersh BJ, et al. An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: A retrospective analysis of outcome prediction. Lancet. 2019; 394(10201): 861–7. DOI: 10.1016/S0140-6736(19)31721-0
- Kashou AH, Rabinstein AA, Attia IZ, Asirvatham SJ, Gersh BJ, Friedman PA, et al. Recurrent cryptogenic stroke: A potential role for an artificial intelligence-enabled electrocardiogram? HeartRhythm Case Rep. 2020; 6(4): 202–5. DOI: 10.1016/j.hrcr.2019.12.013
- Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018; 378(23): 2191–201. DOI: 10.1056/NEJMoa1802686
- Diener HC, Sacco RL, Easton JD, Granger CB, Bernstein RA, Uchiyama S, et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019; 380(20): 1906–17. DOI: 10.1056/NEJMoa1813959
- Noseworthy PA, Attia ZI, Brewer LC, Hayes SN, Yao X, Kapa S, et al. Assessing and Mitigating Bias in Medical Artificial Intelligence: The Effects of Race and Ethnicity on a Deep Learning Model for ECG Analysis. Circ Arrhythm Electrophysiol. 2020; 13(3):
e007988 . DOI: 10.1161/CIRCEP.119.007988 - Steinberg JS, Varma N, Cygankiewicz I, Aziz P, Balsam P, Baranchuk A, et al. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm. 2017; 14(7): e55–e96. DOI: 10.1016/j.hrthm.2017.03.038
- Steinhubl SR, Waalen J, Edwards AM, Ariniello LM, Mehta RR, Ebner GS, et al. Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial. JAMA. 2018; 320(2): 146–55. DOI: 10.1001/jama.2018.8102
- Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014; 370(26): 2467–77. DOI: 10.1056/NEJMoa1311376
- Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014; 370(26): 2478–86. DOI: 10.1056/NEJMoa1313600
- Diederichsen SZ, Haugan KJ, Kronborg C, Graff C, Højberg S, Køber L, et al. Comprehensive Evaluation of Rhythm Monitoring Strategies in Screening for Atrial Fibrillation: Insights From Patients at Risk Monitored Long Term With an Implantable Loop Recorder. Circulation. 2020; 141(19): 1510–22. DOI: 10.1161/CIRCULATIONAHA.119.044407
- Chen Y, Huang QF, Sheng CS, Zhang W, Shao S, Wang D, et al. Detection rate and treatment gap for atrial fibrillation identified through screening in community health centers in China (AF-CATCH): A prospective multicenter study. PLoS Med. 2020; 17(7): e1003146. DOI: 10.1371/journal.pmed.1003146
- Orchard J, Neubeck L, Freedman B, Li J, Webster R, Zwar N, et al. eHealth Tools to Provide Structured Assistance for Atrial Fibrillation Screening, Management, and Guideline-Recommended Therapy in Metropolitan General Practice: The AF – SMART Study. J Am Heart Assoc. 2019; 8(1): e010959. DOI: 10.1161/JAHA.118.010959
- Tarride J-E, Dolovich L, Blackhouse G, Guertin JR, Burke N, Manja V, et al. Screening for atrial fibrillation in Canadian pharmacies: an economic evaluation. CMAJ open. 2017; 5(3): E653–E61. DOI: 10.9778/cmajo.20170042
- Alkmim MB, Figueira RM, Marcolino MS, Cardoso CS, Pena de Abreu M, Cunha LR, et al. Improving patient access to specialized health care: the Telehealth Network of Minas Gerais, Brazil. Bull World Health Organ. 2012; 90(5): 373–8. DOI: 10.2471/BLT.11.099408
- Bunch TJ, Steinberg BA. Revisiting Rate versus Rhythm Control in Atrial Fibrillation — Timing Matters. N Engl J Med; 2020. DOI: 10.1056/NEJMe2027180
- Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med; 2020. DOI: 10.1056/NEJMoa2019422
- Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. Chest. 2010; 137(2): 263–72. DOI: 10.1378/chest.09-1584
- Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, et al. Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. Thromb Haemost. 2018; 118(12): 2171–87. DOI: 10.1055/s-0038-1675400
- Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: A systematic review. Ann Intern Med. 2014; 160(11): 760–73. DOI: 10.7326/M13-1467
- Tamariz LJ, Bass EB. Pharmacological rate control of atrial fibrillation. Cardiol Clin. 2004; 22(1): 35–45. DOI: 10.1016/S0733-8651(03)00111-5
- Nikolaidou T, Channer KS. Chronic atrial fibrillation: A systematic review of medical heart rate control management. Postgrad Med J. 2009; 85(1004): 303–12. DOI: 10.1136/pgmj.2008.068908
- Marshall DA, Levy AR, Vidaillet H, Fenwick E, Slee A, Blackhouse G, et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med. 2004; 141(9): 653–61. DOI: 10.7326/0003-4819-141-9-200411020-00005
- Mkoko P, Bahiru E, Ajijola OA, Bonny A, Chin A. Cardiac arrhythmias in low- and middle-income countries. Cardiovasc Diagn Ther. 2020; 10(2): 350–60. DOI: 10.21037/cdt.2019.09.21
- Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017; 14(10): e275–e444.
- Middeldorp ME, Ariyaratnam J, Lau D, Sanders P. Lifestyle modifications for treatment of atrial fibrillation. Heart. 2020; 106(5): 325–32. DOI: 10.1136/heartjnl-2019-315327
- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J; 2020.
- Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011; 57(3): 313–21. DOI: 10.1016/j.jacc.2010.07.046
- Markey GC, Salter N, Ryan J. Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation. J Emerg Med. 2018; 54(3): 320–7. DOI: 10.1016/j.jemermed.2017.11.016
- Reisinger J, Gatterer E, Lang W, Vanicek T, Eisserer G, Bachleitner T, et al. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J. 2004; 25(15): 1318–24. DOI: 10.1016/j.ehj.2004.04.030
- Zhang N, Guo JH, Zhang H, Li XB, Zhang P, Xn Y. Comparison of intravenous ibutilide vs. propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract. 2005; 59(12): 1395–400. DOI: 10.1111/j.1368-5031.2005.00705.x
- Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008; 117(12): 1518–25. DOI: 10.1161/CIRCULATIONAHA.107.723866
- Conde D, Costabel JP, Caro M, Ferro A, Lambardi F, Corrales Barboza A, et al. Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. Int J Cardiol. 2013; 168(3): 2423–5. DOI: 10.1016/j.ijcard.2013.02.006
- Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Fernandez-Gomez JM, Santos JM, Camacho C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol. 2000; 86(9): 950–3. DOI: 10.1016/S0002-9149(00)01128-0
- Arbelo E, Brugada J, Hindricks G, Maggioni A, Tavazzi L, Vardas P, et al. ESC-EURObservational Research Programme: The Atrial Fibrillation Ablation Pilot Study, conducted by the European Heart Rhythm Association. Europace. 2012; 14(8): 1094–103. DOI: 10.1093/europace/eus153
- Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P, et al. The atrial fibrillation ablation pilot study: A European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J. 2014; 35(22): 1466–78. DOI: 10.1093/eurheartj/ehu001
- Arbelo E, Brugada J, Blomstrom-Lundqvist C, Laroche C, Kautzner J, Pokushalov E, et al. Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. Eur Heart J. 2017; 38(17): 1303–16. DOI: 10.1093/eurheartj/ehw564
- Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Europace. 2018; 20(1): 157–208. DOI: 10.1093/europace/eux275
- Hindricks G, Sepehri Shamloo A, Lenarczyk R, Kalarus Z, Arya A, Kircher S, et al. Catheter ablation of atrial fibrillation: Current status, techniques, outcomes and challenges. Kardiol Pol. 2018; 76(12): 1680–6. DOI: 10.5603/KP.a2018.0216
- Keegan R, Aguinaga L, Fenelon G, Uribe W, Rodriguez Diez G, Scanavacca M, et al. The first Latin American Catheter Ablation Registry. Europace. 2015; 17(5): 794–800. DOI: 10.1093/europace/euu322
- Keegan R, et al. Catheter ablation of atrial fibrillation in Latin America: Results of the first registry of the Latin American Society of Pacing and Electrophysiology Cardiac (SOLAECE). RevUrugCardiol. 2016; 31(1): 165–75.
- Bonny A, Ngantcha M, Scholtz W, Chin A, Nel G, Anzouan-Kacou J-B, et al. Cardiac Arrhythmias in Africa: Epidemiology, Management Challenges, and Perspectives. Journal of the American College of Cardiology. 2019; 73(1): 100–9. DOI: 10.1016/j.jacc.2018.09.084
- Bonny A, Ngantcha M, Yuyun M, Karaye KM, Scholtz W, Suliman A, et al. Cardiac arrhythmia services in Africa from 2011 to 2018: The second report from the Pan African Society of Cardiology working group on cardiac arrhythmias and pacing. Europace. 2020; 22(3): 420–33. DOI: 10.1093/europace/euz354
- Bonny A, Ngantcha M, Yuyun MF, Karaye KM, Scholtz W, Suliman A, et al. Cardiac arrhythmia services in Africa from 2011 to 2018: The second report from the Pan African Society of Cardiology working group on cardiac arrhythmias and pacing. EP Europace. 2020; 22(3): 420–33. DOI: 10.1093/europace/euz354
- Ntep-Gweth M, Zimmermann M, Meiltz A, Kingue S, Ndobo P, Urban P, et al. Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2010; 12(4): 482–7. DOI: 10.1093/europace/euq006
- Ettarh R. Patterns of international collaboration in cardiovascular research in sub-Saharan Africa. Cardiovascular Journal of Africa. 2016; 27(3): 194. DOI: 10.5830/CVJA-2015-082
- Mkoko P, Bahiru E, Ajijola OA, Bonny A, Chin A. Cardiac arrhythmias in low-and middle-income countries. Cardiovascular Diagnosis and Therapy. 2020; 10(2): 350. DOI: 10.21037/cdt.2019.09.21
- Agyepong IA, Sewankambo N, Binagwaho A, Coll-Seck AM, Corrah T, Ezeh A, et al. The path to longer and healthier lives for all Africans by 2030: The Lancet Commission on the future of health in sub-Saharan Africa. The Lancet. 2017; 390(10114): 2803–59. DOI: 10.1016/S0140-6736(17)31509-X
- The World Bank.
Universal Health Coverage (UHC) in Africa: A Framework for Action: Main Report . The World Bank; 2016. - Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, et al. Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J. 2005; 150(2): 288–93. DOI: 10.1016/j.ahj.2004.09.054
- Whitlock RP, Vincent J, Blackall MH, Hirsh J, Fremes S, Novick R, et al. Left Atrial Appendage Occlusion Study II (LAAOS II). Can J Cardiol. 2013; 29(11): 1443–7. DOI: 10.1016/j.cjca.2013.06.015
- Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: A meta-analysis. Eur J Cardiothorac Surg. 2015; 47(5): 847–54. DOI: 10.1093/ejcts/ezu291
- Holmes DR,
Jr. , Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol. 2015; 65(24): 2614–23. DOI: 10.1016/j.jacc.2015.04.025 - Boersma LV, Ince H, Kische S, Pokushalov E, Schmitz T, Schmidt B, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017; 14(9): 1302–8. DOI: 10.1016/j.hrthm.2017.05.038
- Hicks T, Stewart F, Eisinga A. NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open heart. 2016; 3(1):
e000279 . DOI: 10.1136/openhrt-2015-000279 - Laing R, Waning B, Gray A, Ford N, Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. The Lancet. 2003; 361(9370): 1723–9. DOI: 10.1016/S0140-6736(03)13375-2
- Di Cesare M, Jarvis JD, Scarlatescu O, Leng X, Zaidel EJ, Burrone E, et al. NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions. Glob Heart. 2020; 15(1): 67. DOI: 10.5334/gh.774
- Cowan JC, Wu J, Hall M, Orlowski A, West RM, Gale CP. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018; 39(32): 2975–83. DOI: 10.1093/eurheartj/ehy411
- Chao TF, Chiang CE, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan. Circulation. 2018; 138(14): 1485–7. DOI: 10.1161/CIRCULATIONAHA.118.036046
- Lee SR, Choi EK, Han KD, Cha MJ, Oh S, Lip GYH. Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study. PLoS One. 2017; 12(12):
e0189495 . DOI: 10.1371/journal.pone.0189495 - Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010; 376(9745): 975–83. DOI: 10.1016/S0140-6736(10)61194-4
- Gamra H, Murin J, Chiang CE, Naditch-Brûlé L, Brette S, Steg PG. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Arch Cardiovasc Dis. 2014; 107(2): 77–87. DOI: 10.1016/j.acvd.2014.01.001
- Guo J, Guan T, Fan S, Chao B, Wang L, Liu Y. Underuse of Oral Anticoagulants in Patients With Ischemic Stroke and Atrial Fibrillation in China. Am J Cardiol. 2018; 122(12): 2055–61. DOI: 10.1016/j.amjcard.2018.08.057
- Chang SS, Dong JZ, Ma CS, Du X, Wu JH, Tang RB, et al. Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation: The Chinese Atrial Fibrillation Registry Study. Stroke. 2016; 47(7): 1803–10. DOI: 10.1161/STROKEAHA.116.012988
- Karthikeyan G, Connolly SJ, Ntsekhe M, Benz A, Rangarajan S, Lewis G, et al. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. Am Heart J. 2020; 225: 69–77. DOI: 10.1016/j.ahj.2020.03.018
- Guimarães HP, Lopes RD, de Barros ESPGM, Liporace IL, Sampaio RO, Tarasoutchi F, et al. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Engl J Med. 2020; 383(22): 2117–26. DOI: 10.1056/NEJMoa2029603
- Meyer S, Frei CR, Daniels KR, Forcade NA, Bussey M, Bussey-Smith KL, et al. Impact of a new method of warfarin management on patient satisfaction, time, and cost. Pharmacotherapy. 2013; 33(11): 1147–55. DOI: 10.1002/phar.1344
- Barcellona D, Fenu L, Marongiu F. Point-of-care testing INR: An overview. Clin Chem Lab Med. 2017; 55(6): 800–5. DOI: 10.1515/cclm-2016-0381
- Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: Data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013; 2(1):
e000067 . DOI: 10.1161/JAHA.112.000067 - Lowres N, Freedman B. Time to develop guidelines for screening and management of atrial fibrillation in Indigenous Australians. Med J Aust. 2020; 212(5): 212–3. DOI: 10.5694/mja2.50513
- Nedkoff L, Kelty EA, Hung J, Thompson SC, Katzenellenbogen JM. Differences in stroke risk and cardiovascular mortality for Aboriginal and other Australian patients with atrial fibrillation. Med J Aust. 2020; 212(5): 215–21. DOI: 10.5694/mja2.50496
- Gu Y, Doughty RN, Freedman B, Kennelly J, Warren J, Harwood M, et al. Burden of atrial fibrillation in Māori and Pacific people in New Zealand: A cohort study. Intern Med J. 2018; 48(3): 301–9. DOI: 10.1111/imj.13648
- Marcolino MS, Polanczyk CA, Bovendorp AC, Marques NS, Silva LA, Turquia CP, et al. Economic evaluation of the new oral anticoagulants for the prevention of thromboembolic events: A cost-minimization analysis. Sao Paulo Med J. 2016; 134(4): 322–9. DOI: 10.1590/1516-3180.2016.0019260216
- Deshpande CG, Kogut S, Laforge R, Willey C. Impact of medication adherence on risk of ischemic stroke, major bleeding and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants. Curr Med Res Opin. 2018; 34(7): 1285–92. DOI: 10.1080/03007995.2018.1428543
- Alberts MJ, Peacock WF, Fields LE, Bunz TJ, Nguyen E, Milentijevic D, et al. Association between once- and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke. Int J Cardiol. 2016; 215: 11–3. DOI: 10.1016/j.ijcard.2016.03.212
- Borne RT, O’Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: Findings from the veterans health administration. BMC Cardiovasc Disord. 2017; 17(1): 236. DOI: 10.1186/s12872-017-0671-6
- Manzoor BS, Lee TA, Sharp LK, Walton SM, Galanter WL, Nutescu EA. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. Pharmacotherapy. 2017; 37(10): 1221–30. DOI: 10.1002/phar.1989
- Maura G, Billionnet C, Alla F, Gagne JJ, Pariente A. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. Pharmacotherapy. 2018; 38(1): 6–18. DOI: 10.1002/phar.2046
- Mueller T, Alvarez-Madrazo S, Robertson C, Bennie M. Use of direct oral anticoagulants in patients with atrial fibrillation in Scotland: Applying a coherent framework to drug utilisation studies. Pharmacoepidemiol Drug Saf. 2017; 26(11): 1378–86. DOI: 10.1002/pds.4272
- Rodriguez-Bernal CL, Peiro S, Hurtado I, Garcia-Sempere A, Sanfelix-Gimeno G. Primary Nonadherence to Oral Anticoagulants in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort. J Manag Care Spec Pharm. 2018; 24(5): 440–8. DOI: 10.18553/jmcp.2018.24.5.440
- Emren SV, Senoz O, Bilgin M, Beton O, Aslan A, Taskin U, et al. Drug Adherence in Patients with Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb Hemost. 2018; 24(3): 525–31. DOI: 10.1177/1076029617693940
- Buchholz A, Ueberham L, Gorczynska K, Dinov B, Hilbert S, Dagres N, et al. Initial apixaban dosing in patients with atrial fibrillation. Clin Cardiol. 2018; 41(5): 671–6. DOI: 10.1002/clc.22949
- Harper P, Pollock D, Stephens M. Dabigatran persistence and adherence in New Zealand: a nationwide retrospective observational study. BMJ Open. 2018; 8(4):
e020212 . DOI: 10.1136/bmjopen-2017-020212 - Reading SR, Black MH, Singer DE, Go AS, Fang MC, Udaltsova N, et al. Risk factors for medication non-adherence among atrial fibrillation patients. BMC Cardiovasc Disord. 2019; 19(1): 38. DOI: 10.1186/s12872-019-1019-1
- Gomez-Lumbreras A, Cortes J, Giner-Soriano M, Quijada-Manuitt MA, Morros R. Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia. J Cardiovasc Pharmacol Ther. 2018; 23(6): 494–501. DOI: 10.1177/1074248418778544
- Nobili A, Marengoni A, Tettamanti M, Salerno F, Pasina L, Franchi C, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: Results from the REPOSI study. Eur J Intern Med. 2011; 22(6): 597–602. DOI: 10.1016/j.ejim.2011.08.029
- Noseworthy PA, Brito JP, Kunneman M, Hargraves IG, Zeballos-Palacios C, Montori VM, et al. Shared decision-making in atrial fibrillation: Navigating complex issues in partnership with the patient. J Interv Card Electrophysiol; 2018. DOI: 10.1007/s10840-018-0465-5
- Pritchett RV, Bem D, Turner GM, Thomas GN, Clarke JL, Fellows R, et al. Improving the Prescription of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. Thromb Haemost. 2019; 119(2): 294–307. DOI: 10.1055/s-0038-1676835
- Martinez C, Wallenhorst C, Rietbrock S, Freedman B. Ischemic Stroke and Transient Ischemic Attack Risk Following Vitamin K Antagonist Cessation in Newly Diagnosed Atrial Fibrillation: A Cohort Study. J Am Heart Assoc. 2020; 9(2):
e014376 . DOI: 10.1161/JAHA.119.014376 - Lowres N, Giskes K, Freedman B. Next frontier for stroke prevention in atrial fibrillation: Ensuring anticoagulant persistence. Heart; 2020. DOI: 10.1136/heartjnl-2020-318392
- Nutbeam D. The evolving concept of health literacy. Soc Sci Med. 2008; 67(12): 2072–8. DOI: 10.1016/j.socscimed.2008.09.050
- Lane DA, Meyerhoff J, Rohner U, Lip GYH. Atrial fibrillation patient preferences for oral anticoagulation and stroke knowledge: Results of a conjoint analysis. Clin Cardiol. 2018; 41(6): 855–61. DOI: 10.1002/clc.22971
- Hoe R, Lin W, Bautista MAC, Vrijhoef HJM, Lim TW. Validation of a questionnaire measuring patient knowledge of atrial fibrillation in an Asian cohort. Heart Asia. 2019; 11(1):
e011143 . DOI: 10.1136/heartasia-2018-011143 - Amara W, Larsen TB, Sciaraffia E, Hernández Madrid A, Chen J, Estner H, et al. Patients’ attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. EP Europace. 2015; 18(1): 151–5. DOI: 10.1093/europace/euv317
- Seligman WH, Das-Gupta Z, Jobi-Odeneye AO, Arbelo E, Banerjee A, Bollmann A, et al. Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group. Eur Heart J. 2020; 41(10): 1132–40. DOI: 10.1093/eurheartj/ehz871
- Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, et al. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace; 2020.
- Smet L, Heggermont WA, Goossens E, Eeckloo K, Vander Stichele R, De Potter T, et al. Adherence, knowledge, and perception about oral anticoagulants in patients with atrial fibrillation at high risk for thromboembolic events after radiofrequency ablation. J Adv Nurs. 2018; 74(11): 2577–87. DOI: 10.1111/jan.13780
- Maikranz V, Siebenhofer A, Ulrich L-R, Mergenthal K, Schulz-Rothe S, Kemperdick B, et al. Does a complex intervention increase patient knowledge about oral anticoagulation? A cluster-randomised controlled trial. BMC Fam Pract. 2017; 18(1): 15. DOI: 10.1186/s12875-017-0588-2
- Desteghe L, Germeys J, Vijgen J, Koopman P, Dilling-Boer D, Schurmans J, et al. Effectiveness and usability of an online tailored education platform for atrial fibrillation patients undergoing a direct current cardioversion or pulmonary vein isolation. Int J Cardiol. 2018; 272: 123–9. DOI: 10.1016/j.ijcard.2018.07.065
- Marquez-Contreras E, Martell-Claros N, Marquez-Rivero S, Hermida-Campa E, Gracia-Diez C, Sanchez-Lopez E, et al. Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: Education and drug intake reminders (FACILITA study). Curr Med Res Opin. 2018; 34(7): 1301–8. DOI: 10.1080/03007995.2018.1435519
- Vinereanu D, Lopes RD, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, et al. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): An international, cluster-randomised trial. The Lancet. 2017; 390(10104): 1737–46. DOI: 10.1016/S0140-6736(17)32165-7
- Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, et al. Mobile health technology to improve care for patients with atrial fibrillation. J Am Coll Cardiol. 2020; 75(13): 1523–34. DOI: 10.1016/j.jacc.2020.01.052
- Eckman MH, Costea A, Attari M, Munjal J, Wise RE, Knochelmann C, et al. Shared decision-making tool for thromboprophylaxis in atrial fibrillation – A feasibility study. Am Heart J. 2018; 199: 13–21. DOI: 10.1016/j.ahj.2018.01.003
- Stephan LS, Almeida ED, Guimaraes RB, Ley AG, Mathias RG, Assis MV, et al. Oral Anticoagulation in Atrial Fibrillation: Development and Evaluation of a Mobile Health Application to Support Shared Decision-Making. Arq Bras Cardiol. 2018; 110(1): 7–15. DOI: 10.5935/abc.20170181
- Rolls CA, Obamiro KO, Chalmers L, Bereznicki LRE. The relationship between knowledge, health literacy, and adherence among patients taking oral anticoagulants for stroke thromboprophylaxis in atrial fibrillation. Cardiovasc Ther. 2017; 35(6). DOI: 10.1111/1755-5922.12304
- Heidbuchel H, Dagres N, Antz M, Kuck K-H, Lazure P, Murray S, et al. Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: A European Society of Cardiology international educational needs assessment. Ep Europace. 2018; 20(12): 1919–28. DOI: 10.1093/europace/euy039
- Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. EP Europace. 2018; 20(8): 1231–42. DOI: 10.1093/europace/euy054
- Orchard JJ, Neubeck L, Orchard JW, Puranik R, Raju H, Freedman B, et al. ECG-based cardiac screening programs: Legal, ethical, and logistical considerations. Heart Rhythm. 2019; 16(10): 1584–91. DOI: 10.1016/j.hrthm.2019.03.025
- Zhang L, Gallagher R, Neubeck L. Health-related quality of life in atrial fibrillation patients over 65 years: a review. Eur J Prev Cardiol. 2015; 22(8): 987–1002. DOI: 10.1177/2047487314538855
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50(5): e1–e88.
- Kirchhof P. The future of atrial fibrillation management: Integrated care and stratified therapy. The Lancet. 2017; 390(10105): 1873–87. DOI: 10.1016/S0140-6736(17)31072-3
- Pastori D, Menichelli D, Violi F, Pignatelli P, G YHL. The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: A potential sex-based difference. The ATHERO-AF study. Eur J Intern Med; 2020. DOI: 10.1093/ehjci/ehaa946.0346
- Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016; 388(10050): 1161–9. DOI: 10.1016/S0140-6736(16)30968-0
- Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. The Lancet. 2015; 386(9989): 154–62. DOI: 10.1016/S0140-6736(14)61774-8
- Rahman F, Wang N, Yin X, Ellinor PT, Lubitz SA, LeLorier PA, et al. Atrial flutter: Clinical risk factors and adverse outcomes in the Framingham Heart Study. Heart Rhythm. 2016; 13(1): 233–40. DOI: 10.1016/j.hrthm.2015.07.031
- Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA, et al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. Circulation. 2020; 141(16): e750–e72. DOI: 10.1161/CIR.0000000000000748
- Wong JA, Conen D, Van Gelder IC, McIntyre WF, Crijns HJ, Wang J, et al. Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. J Am Coll Cardiol. 2018; 71(23): 2603–11. DOI: 10.1016/j.jacc.2018.03.519
- Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008; 358(25): 2667–77. DOI: 10.1056/NEJMoa0708789
- Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018; 378(5): 417–27. DOI: 10.1056/NEJMoa1707855
- Gaita F, Leclercq JF, Schumacher B, Scaglione M, Toso E, Halimi F, et al. Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Electrophysiol. 2011; 22(9): 961–8. DOI: 10.1111/j.1540-8167.2011.02050.x
- Conen D, Rodondi N, Müller A, Beer JH, Ammann P, Moschovitis G, et al. Relationships of Overt and Silent Brain Lesions with Cognitive Function in Patients with Atrial Fibrillation. J Am Coll Cardiol. 2019; 73(9): 989–99. DOI: 10.1016/j.jacc.2018.12.039
- Thacker EL, McKnight B, Psaty BM, Longstreth WT,
Jr. , Sitlani CM, Dublin S, et al. Atrial fibrillation and cognitive decline: A longitudinal cohort study. Neurology. 2013; 81(2): 119–25. DOI: 10.1212/WNL.0b013e31829a33d1 - Lopes RD, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, et al. Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients with Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. Am Heart J. 2017; 189: 137–45. DOI: 10.1016/j.ahj.2017.04.008
- Rivard L, Khairy P, Talajic M, Tardif JC, Nattel S, Bherer L, et al. Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. Can J Cardiol. 2019; 35(8): 1069–77. DOI: 10.1016/j.cjca.2019.04.022
- Claes N, Van Laethem C, Goethals M, Goethals P, Mairesse G, Schwagten B, et al. Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. Acta Cardiol. 2012; 67(3): 273–8. DOI: 10.1080/AC.67.3.2160714
- Zhou Z, Hu D. An Epidemiological Study on the Prevalence of Atrial Fibrillation in the Chinese Population of Mainland China. J Epidemiol. 2008; 18(5): 209–16. DOI: 10.2188/jea.JE2008021
- Wang Z, Chen Z, Wang X, Zhang L, Li S, Tian Y, et al. The Disease Burden of Atrial Fibrillation in China from a National Cross-sectional Survey. Am J Cardiol. 2018; 122(5): 793–8. DOI: 10.1016/j.amjcard.2018.05.015
- Fitzmaurice DA, Hobbs FDR, Jowett S, Mant J, Murray ET, Holder R, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: Cluster randomised controlled trial. BMJ (Clinical research ed). 2007; 335(7616): 383. DOI: 10.1136/bmj.39280.660567.55
- Davis RC, Hobbs FDR, Kenkre JE, Roalfe AK, Iles R, Lip GYH, et al. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. EP Europace. 2012; 14(11): 1553–9. DOI: 10.1093/europace/eus087
- Schnabel RB, Wilde S, Wild PS, Munzel T, Blankenberg S. Atrial fibrillation: Its prevalence and risk factor profile in the German general population. Deutsches Ärzteblatt International. 2012; 109(16): 293. DOI: 10.3238/arztebl.2012.0293
- Bilato C, Corti M-C, Baggio G, Rampazzo D, Cutolo A, Iliceto S, et al. Prevalence, Functional Impact, and Mortality of Atrial Fibrillation in an Older Italian Population (from the Pro.V.A. Study). Am J Cardiol. 2009; 104(8): 1092–7. DOI: 10.1016/j.amjcard.2009.05.058
- Di Carlo A, Bellino L, Consoli D, Mori F, Zaninelli A, Baldereschi M, et al. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: The FAI Project. Europace. 2019; 21(10): 1468–75. DOI: 10.1093/europace/euz141
- Bonhorst D, Mendes M, Adragão P, De Sousa J, Primo J, Leiria E, et al. Prevalence of atrial fibrillation in the Portuguese population aged 40 and over: The FAMA study. Rev Port Cardiol. 2010; 29(3): 331–50.
- Monteiro P. The SAFIRA study: A reflection on the prevalence and treatment patterns of atrial fibrillation and cardiovascular risk factors in 7500 elderly subjects. Revista Portuguesa de Cardiologia (English edition). 2018; 37(4): 307–13. DOI: 10.1016/j.repce.2017.08.006
- Gómez-Doblas JJ, Muñiz J, Martin JJA, Rodríguez-Roca G, Lobos JM, Awamleh P, et al. Prevalence of Atrial Fibrillation in Spain. OFRECE Study Results. Revista Española de Cardiología (English Edition). 2014; 67(4): 259–69. DOI: 10.1016/j.rec.2013.07.014
- Joan Sala RM, Marrugat J, Pena A. Prevalencia de fibrilación auricular en la provincia de Girona: el Estudio REGICOR. Rev Esp Cardiol. 2001; 54(10): 1240. DOI: 10.1016/S0300-8932(01)76486-X
- Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise Screening of Atrial Fibrillation in a 75-Year-Old Population. Circulation. 2013; 127(8): 930–7. DOI: 10.1161/CIRCULATIONAHA.112.126656
- Andersson P, Löndahl M, Abdon N-J, Terent A. The prevalence of atrial fibrillation in a geographically well-defined population in Northern Sweden: implications for anticoagulation prophylaxis. J Intern Med. 2012; 272(2): 170–6. DOI: 10.1111/j.1365-2796.2012.02519.x
- Koopman JJE, van Bodegom D, Westendorp RGJ, Jukema JW. Scarcity of atrial fibrillation in a traditional African population: A community-based study. BMC Cardiovasc Disord. 2014; 14(1): 87. DOI: 10.1186/1471-2261-14-87
- Dewhurst MJ, Adams PC, Gray WK, Dewhurst F, Orega GP, Chaote P, et al. Strikingly low prevalence of atrial fibrillation in elderly Tanzanians. J Am Geriatr Soc. 2012; 60(6): 1135–40. DOI: 10.1111/j.1532-5415.2012.03963.x
- Tegene E, Tadesse I, Markos Y, Gobena T. Prevalence and risk factors for atrial fibrillation and its anticoagulant requirement in adults aged ≥40 in Jimma Town, Southwest Ethiopia: A community based cross-sectional study. Int J Cardiol Heart Vasc. 2019; 22: 199–204. DOI: 10.1016/j.ijcha.2019.02.003
- Allan V, Honarbakhsh S, Casas JP, Wallace J, Hunter R, Schilling R, et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost. 2017; 117(5): 837–50. DOI: 10.1160/TH16-11-0825
- Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019; 139(10): e56–e528.
- Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, et al. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options—A report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2012; 14(1): 8–27. DOI: 10.1093/europace/eur241
- Chang SH, Kuo CF, Chou IJ, See LC, Yu KH, Luo SF, et al. Association of a Family History of Atrial Fibrillation with Incidence and Outcomes of Atrial Fibrillation: A Population-Based Family Cohort Study. JAMA Cardiol. 2017; 2(8): 863–70. DOI: 10.1001/jamacardio.2017.1855
- Fox CS, Parise H, D’Agostino RB,
Sr. , Lloyd-Jones DM, Vasan RS, Wang TJ, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 2004; 291(23): 2851–5. DOI: 10.1001/jama.291.23.2851 - Lubitz SA, Yin X, Fontes JD, Magnani JW, Rienstra M, Pai M, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010; 304(20): 2263–9. DOI: 10.1001/jama.2010.1690
- Zoller B, Ohlsson H, Sundquist J, Sundquist K. High familial risk of atrial fibrillation/atrial flutter in multiplex families: a nationwide family study in Sweden. J Am Heart Assoc. 2012; 2(1): e003384. DOI: 10.1161/JAHA.112.003384
- Giacomantonio NB, Bredin SS, Foulds HJ, Warburton DE. A systematic review of the health benefits of exercise rehabilitation in persons living with atrial fibrillation. Can J Cardiol. 2013; 29(4): 483–91. DOI: 10.1016/j.cjca.2012.07.003
- Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaelsson K, et al. Risk of arrhythmias in 52 755 long-distance cross-country skiers: A cohort study. Eur Heart J. 2013; 34(47): 3624–31. DOI: 10.1093/eurheartj/eht188
- Shamloo AS, Dagres N, Arya A, Hindricks G. Atrial fibrillation: A review of modifiable risk factors and preventive strategies. Rom J Intern Med. 2019; 57(2): 99–109. DOI: 10.2478/rjim-2018-0045
- Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994; 74(3): 236–41. DOI: 10.1016/0002-9149(94)90363-8
- Santhanakrishnan R, Wang N, Larson MG, Magnani JW, McManus DD, Lubitz SA, et al. Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation. 2016; 133(5): 484–92. DOI: 10.1161/CIRCULATIONAHA.115.018614
- Lip GYH, Collet JP, de Caterina R, Fauchier L, Lane DA, Larsen TB, et al. Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Thromb Haemost. 2017; 117(12): 2215–36. DOI: 10.1160/TH-17-10-0709
- Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994; 271(11): 840–4. DOI: 10.1001/jama.1994.03510350050036
- Loomba RS, Buelow MW, Aggarwal S, Arora RR, Kovach J, Ginde S. Arrhythmias in Adults with Congenital Heart Disease: What Are Risk Factors for Specific Arrhythmias? Pacing Clin Electrophysiol. 2017; 40(4): 353–61. DOI: 10.1111/pace.12983
- Alonso A, Jensen PN, Lopez FL, Chen LY, Psaty BM, Folsom AR, et al. Association of sick sinus syndrome with incident cardiovascular disease and mortality: the Atherosclerosis Risk in Communities study and Cardiovascular Health Study. PLoS One. 2014; 9(10):
e109662 . DOI: 10.1371/journal.pone.0109662 - Aune D, Feng T, Schlesinger S, Janszky I, Norat T, Riboli E. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: A systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018; 32(5): 501–11. DOI: 10.1016/j.jdiacomp.2018.02.004
- Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123(25): 2946–53. DOI: 10.1161/CIRCULATIONAHA.111.020982
- Bansal N, Zelnick LR, Alonso A, Benjamin EJ, de Boer IH, Deo R, et al. eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study. Clin J Am Soc Nephrol. 2017; 12(9): 1386–98. DOI: 10.2215/CJN.01860217
- Asad Z, Abbas M, Javed I, Korantzopoulos P, Stavrakis S. Obesity is associated with incident atrial fibrillation independent of gender: A meta-analysis. J Cardiovasc Electrophysiol. 2018; 29(5): 725–32. DOI: 10.1111/jce.13458
- Aune D, Sen A, Schlesinger S, Norat T, Janszky I, Romundstad P, et al. Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: A systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2017; 32(3): 181–92. DOI: 10.1007/s10654-017-0232-4
- Desai R, Patel U, Singh S, Bhuva R, Fong HK, Nunna P, et al. The burden and impact of arrhythmia in chronic obstructive pulmonary disease: Insights from the National Inpatient Sample. Int J Cardiol. 2019; 281: 49–55. DOI: 10.1016/j.ijcard.2019.01.074
- Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330–93. DOI: 10.1093/eurheartj/ehy136
DOI: https://doi.org/10.5334/gh.1023 | Journal eISSN: 2211-8179
Language: English
Submitted on: Mar 3, 2021
Accepted on: May 6, 2021
Published on: May 27, 2021
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
© 2021 Ben Freedman, Gerhard Hindricks, Amitava Banerjee, Adrian Baranchuk, Chi Keong Ching, Xin Du, Donna Fitzsimons, Jeff S. Healey, Takanori Ikeda, Trudie C. A. Lobban, Amam Mbakwem, Calambur Narasimhan, Lis Neubeck, Peter Noseworthy, Daniel M. Philbin, Fausto J. Pinto, Joselyn Rwebembera, Renate B. Schnabel, Jesper Hastrup Svendsen, Luis Aguinaga, Elena Arbelo, Michael Böhm, Hasan Ali Farhan, F. D. Richard Hobbs, Antoni Martínez-Rubio, Claudio Militello, Nitish Naik, Jean Jacques Noubiap, Pablo Perel, Daniel José Piñero, Antonio Luiz Ribeiro, Janina Stepinska, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.